Volume | 890,189 |
|
|||||
News | - | ||||||
Day High | 2.45 | Low High |
|||||
Day Low | 2.295 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Taysha Gene Therapies Inc | TSHA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.35 | 2.295 | 2.45 | 2.39 | 2.30 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,562 | 890,189 | $ 2.40 | $ 2,135,185 | - | 0.50 - 3.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:00:01 | 30 | $ 2.3513 | USD |
Taysha Gene Therapies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
446.83M | 186.96M | - | 15.45M | -111.57M | -0.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Taysha Gene Therapies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TSHA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.40 | 2.61 | 2.165 | 2.38 | 1,412,798 | -0.01 | -0.42% |
1 Month | 2.83 | 3.40 | 2.165 | 2.77 | 1,905,064 | -0.44 | -15.55% |
3 Months | 1.54 | 3.55 | 1.41 | 2.66 | 2,963,640 | 0.85 | 55.19% |
6 Months | 2.535 | 3.55 | 1.27 | 2.24 | 2,511,233 | -0.145 | -5.72% |
1 Year | 0.65 | 3.89 | 0.50 | 2.28 | 2,647,529 | 1.74 | 267.69% |
3 Years | 22.94 | 26.99 | 0.50 | 2.89 | 1,240,971 | -20.55 | -89.58% |
5 Years | 22.25 | 33.84 | 0.50 | 3.31 | 1,061,003 | -19.86 | -89.26% |
Taysha Gene Therapies Description
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. |